Lupin’s Deal For Soft-Mist Inhalation Tech Gives Access To Spiriva Respimat Platform
Partners With Biomm For Neulasta Biosimilar In Brazil
Executive Summary
With global rights to TTP's soft-mist inhalation platform, Lupin gets access to the drug delivery system used by Boehringer Ingelheim for Spiriva Respimat and it will be interesting to watch pricing as Lupin leverages the aerosolization technology across respiratory products. Meanwhile, the company has entered a partnership with Biomm for marketing its Neulasta biosimilar in Brazil.
You may also be interested in...
Spiriva Generic Must Deliver To Maintain Exit Margin Estimates At Lupin
The performance of its recently-launched Spiriva generic will be crucial for Lupin’s future performance, as it forecasts year-end exit margins in the high teens.
Lupin Rolls Out Spiriva Generic In US, Looks To Take Back From Respimat
Indian respiratory player Lupin has begun shipping its US generic version of Boehringer Ingelheim’s Spiriva HandiHaler, amid plans both to capture share from the originator’s follow-on soft mist inhalation brand and continue development of its own Respimat rival product.
Lupin Counts On Generic Spiriva Launch In Q4 To Turn US Tide
Even as it prepares for competition from an authorized generic, Lupin expects a launch of its generic to Boehringer’s blockbuster Spiriva in the fourth quarter of FY23. It hopes the launch will help its position in the US, where it has exited low margin products amid heightened competition, leading in turn to manufacturing job losses in India